46,411 Shares in Tempus AI, Inc. $TEM Purchased by Headlands Technologies LLC

Headlands Technologies LLC purchased a new position in Tempus AI, Inc. (NASDAQ:TEM) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 46,411 shares of the company’s stock, valued at approximately $2,689,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. JPL Wealth Management LLC acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new stake in Tempus AI during the fourth quarter worth approximately $27,000. Harvest Fund Management Co. Ltd acquired a new position in Tempus AI in the third quarter worth approximately $38,000. Danske Bank A S bought a new position in shares of Tempus AI in the third quarter valued at $48,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Tempus AI during the 3rd quarter valued at $52,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of TEM stock opened at $64.04 on Monday. The company has a market capitalization of $11.56 billion, a price-to-earnings ratio of -44.47 and a beta of 3.58. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The stock’s fifty day simple moving average is $54.63 and its 200-day simple moving average is $51.76.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period last year, the company posted ($0.22) EPS. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, sell-side analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00. Following the completion of the sale, the chief executive officer owned 47,420 shares in the company, valued at $3,319,400. This represents a 23.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 26,313 shares of Tempus AI stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This trade represents a 19.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,040,988 shares of company stock valued at $56,756,417 over the last ninety days. Insiders own 24.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TEM shares. Piper Sandler decreased their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a report on Tuesday, August 4th. Wolfe Research initiated coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.69.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.